Eluminex Biosciences Closes $40+ Million Series B Financing

Series B Proceeds Will Enable Continued Development of Innovative
Ophthalmic Assets and Recombinant Human Collagen Technology

Suzhou, China, February 28, 2023 / San Francisco, USA (PR Newswire) – Eluminex Biosciences (Suzhou) Limited (Eluminex) officially announced today the closing of a Series B financing of over $40 million (USD). Financing was led by Cenova Capital with additional participation from Guangzhou Yuexiu Industrial Investment Fund Management, 3E Bioventures Capital, Oriza Holdings, and Series A investors.

Eluminex is a clinical-stage biotechnology company dedicated to the research and development of global innovative therapeutics with a major focus in ophthalmology and recombinant human collagen technology. Its headquarters and research and development center are located in BioBAY of Suzhou Industrial Park, China, with a clinical and registration center located in South San Francisco, California.

Dr. Jinzhong Zhang, Founder, Chairman and CEO of Eluminex, said: “We have made substantial pipeline progress since our $50 million Series A closure in November 2020, which was co-led by Lilly Asia Ventures, Hillhouse Capital, and Quan Capital. With the Series B raise, the Company will use the proceeds to further mature our innovative ophthalmic pipeline as well as the recombinant human collagen technology platform to meet the needs of patients in China and globally. We are grateful to the four well-known institutional investors and current shareholders for their recognition and support of Eluminex.”

Eluminex’s pipeline programs include novel multi-targeted antibody molecules for vision-threatening retinal diseases, an oral small molecule for rare inherited pediatric retinal dystrophies, and the clinical development and manufacturing of recombinant human collagen-based products with the potential to be world’s first biosynthetic cornea for the treatment of corneal stromal blinding diseases. The Company is currently building a GMP facility in BioBAY of Suzhou Industrial Park for the manufacturing of the recombinant human collagen biosynthetic cornea and other collagen-based products and is expected to operate in mid-2023.

About Eluminex Biosciences (Suzhou) Limited

Founded in February 2020, Eluminex Biosciences (Suzhou) Limited is a global biotechnology company focusing on ophthalmic diseases and recombinant human collagen technology. The company’s headquarters and research and development center are located in BioBAY of Suzhou

Industrial Park, with a US-campus based in South San Francisco, California. For more information, visit www.eluminexbio.com.

About Cenova Capital

Headquartered in Shanghai, Cenova Capital is one of the earliest healthcare funds dedicated to early and growth-stage investments in the life sciences and healthcare sectors in China. Since inception in 2010, Cenova now has 7 funds under management with investments in healthcare services, pharmaceuticals, medical devices and digital health. Cenova's investors are mainly large domestic and international institutional investors including Asian sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies.

About 3E Bioventures Capital

3E Bioventures Capital is dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics. 3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency. The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.

Contact for Investors/Media:

info@eluminexbio.com

典晶生物完成超过 4000 万美元 B 轮融资，持续聚力眼科创新疗法及重组人胶原蛋白技术

2023 年 2 月 28 日，中国苏州/美国旧金山 – 典晶生物医药科技（苏州）有限公司（典晶生物）宣布完成超过 4000 万美元 B 轮融资，用于推进生物合成角膜及多个眼科创新药物的临床研究。此轮融资由千骥资本领投，越秀产业基金、本草资本和元禾控股跟投，现有股东继续加持。舟渡资本在本次交易中担任典晶生物的独家财务顾问。

典晶生物成立于 2020 年初，是一家临床阶段的生物技术公司，公司总部和研发中心位于苏州工业园区生物医药产业园，在美国旧金山湾区设有国际临床和注册中心。典晶生物创始人，董事长和首席执行官张金忠博士曾在美国知名大学担任眼科学助理教授，并先后在美国博士伦、日本参天制药和在纳斯达克上市的两家美国生物技术公司担任高级领导职位。典晶生物核心管理团队成员在全球著名生物医药公司有平均超过 20 年从事创新药和医疗器械研发的经验，曾领导和参与了数十个产品的研发和上市，包括年销售额达几十亿美金的重磅产品。

典晶生物的一个聚焦方向是全球领先的重组人胶原蛋白技术。公司通过合成生物学技术表达具有三股螺旋结构的全长 III 型人胶原蛋白，并掌握了规模化生产工艺。以此为材料制成的生物合成角膜可以治疗与角膜盲相关的视力缺陷，解决捐献角膜严重不足的问题，目前已启动了全球第一个生物合成角膜三类医疗器械注册临床试验。除生物合成角膜外，具有三股螺旋结构的重组 III 型人胶原蛋白还在其它组织再生医学领域有着广泛的应用前景。

典晶生物于 2020 年底完成 5000 万美元的 A 轮融资，由礼来亚洲基金，高瓴创投和泉创资本共同领投。在过去两年多的时间里，公司在团队和管线建设方面都取得了令人瞩目的成绩，将利用 B 轮资金继续开发全球创新的眼科管线和国际领先的重组人胶原蛋白技术平台，以满足中国和全球患者对于眼部疾病和医用胶原蛋白产品的需求。公司非常感谢四家知名投资机构以及原有股东对典晶生物的认可和支持。

千骥资本董事总经理张春燕表示：“典晶团队凭借在眼科创新疗法的深厚积累和经验，在

短短两年多的时间内，建立了两大技术平台——全长人胶原蛋白生物合成平台及多靶点双抗研发平台，并将相关管线推进至临床阶段，我们非常看好团队的研发及执行能力。希望本轮投资能协助公司更快地推动产品的研发，为患者带来更优的解决方案。

关于典晶生物医药科技（苏州）有限公司

典晶生物 (Eluminex Biosciences Limited) 成立于 2020 年 2 月，是一家专注于眼科疾病和重组人胶原蛋白技术的生物医药公司。典晶生物由一支经验丰富的团队领导，旨在建立创新和可持续发展的产品管线，以解决未被满足的临床需求，惠及中国和全球眼部疾病和其他患者。公司总部和研发中心位于苏州工业园区，在美国旧金山湾区设有国际临床和注册中心。如需了解更多信息，请访问 www.eluminexbio.com。

关于千骥资本

千骥资本成立于 2010 年，是国内最早从事医疗健康及生命科学领域投资的专业基金之一，致力于促进中国医疗产业的转化升级和革新。千骥资本目前管理七支健康医疗产业基金，基金出资人为国际及国内知名的机构投资者，包括亚洲主权财富基金、政府机构、国内外保险和金融机构、跨国企业。

关于越秀产业基金

广州越秀产业投资基金管理股份有限公司（简称“越秀产业基金”）成立于 2011 年，是越秀资本旗下的私募投资基金管理平台。截至目前，公司累计基金管理规模超过千亿元。经过多年市场化、专业化的发展，公司形成了“一核（母基金投资）两翼（股权投资、夹层投资）”的业务布局，成长为粤港澳大湾区领先的产业资本运营商。

关于本草资本

本草资本是一家致力于投资全球领先生命科学及医疗健康企业的专业化基金，侧重于创新医药和交叉创新的医疗器械和诊断技术两大投资方向。核心创始团队均为海外生物医药相关专业博士，拥有医药生物科技行业多年实践积累以及国内外十年以上的成功投资和创业经验，兼具专业背景、行业经验和国际视野。本草资本是人民币和美元双币种基金管理人，累计投资和孵化 90 余家境内外医疗创新企业，在北京、上海、硅谷设有办公室。本

草资本秉持“成就伟大医疗健康企业，树立国际专业投资品牌”的愿景，为优秀的创业团队赋能助力，为投资人带来优异的业绩回报。

关于元禾控股

苏州元禾控股股份有限公司（以下简称“元禾控股”）自 2001 年成立起专注于股权投资领域，管理基金规模超千亿元，是国内领先的股权投资机构之一。自成立起，重点关注集成电路、生物医药、人工智能、纳米技术应用等新兴产业投资机会，坚持扶持实体产业，促进产业转型升级。目前，直接投资项目超 1250 个，元禾母基金投资子基金 153 只。